Literature DB >> 2025313

Collagen-induced arthritis in an outbred group of rhesus monkeys comprising responder and nonresponder animals. Relationship between the course of arthritis and collagen-specific immunity.

N P Bakker1, M G van Erck, C A Botman, M Jonker, B A 't Hart.   

Abstract

It is speculated that the autoimmune response to type II collagen (CII) is a driving force in the pathogenesis of human rheumatoid arthritis (RA). In this report, we describe the relationship between the induction of collagen arthritis and the CII-specific humoral, as well as cellular, immune response in rhesus monkeys. Ten of 14 monkeys immunized with bovine type II collagen (B-CII) developed polyarthritis. Susceptible animals showed a T cell response to B-CII; resistant animals did not. After the primary immunization, the humoral response to B-CII, as well as to rhesus monkey type II collagen, was dominated by antibodies of the IgM isotype in the susceptible animals and by antibodies of the IgG isotype in the resistant animals. Because of the close phylogenic relationship between the rhesus monkey and humans, these data contribute valuable information about the role of CII-specific immunity in the pathogenesis of human RA.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2025313     DOI: 10.1002/art.1780340514

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  17 in total

1.  Prophylactic and therapeutic effects of a humanized monoclonal antibody against the IL-2 receptor (DACLIZUMAB) on collagen-induced arthritis (CIA) in rhesus monkeys.

Authors:  H P Brok; J M Tekoppele; J Hakimi; J A Kerwin; E M Nijenhuis; C W De Groot; R E Bontrop; B A 't Hart
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

2.  Identification of antibody epitopes in the CB-11 peptide of bovine type II collagen recognized by sera from arthritis-susceptible and -resistant rhesus monkeys.

Authors:  S Turner; N P Bakker; B A t Hart; P J Holt; K Morgan
Journal:  Clin Exp Immunol       Date:  1994-05       Impact factor: 4.330

Review 3.  Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody.

Authors:  K Yoshizaki; N Nishimoto; M Mihara; T Kishimoto
Journal:  Springer Semin Immunopathol       Date:  1998

Review 4.  Gene therapy for rheumatoid arthritis.

Authors:  P D Robbins; C H Evans; Y Chernajovsky
Journal:  Springer Semin Immunopathol       Date:  1998

5.  3rd International Symposium on the Immunotherapy of the Rheumatic Diseases. 10-14 May 1995, Cyprus. Abstracts.

Authors: 
Journal:  Ann Rheum Dis       Date:  1995-09       Impact factor: 19.103

Review 6.  Animal models for osteoarthritis: processes, problems and prospects.

Authors:  K P Pritzker
Journal:  Ann Rheum Dis       Date:  1994-06       Impact factor: 19.103

7.  In vivo treatment with a monoclonal chimeric anti-CD4 antibody results in prolonged depletion of circulating CD4+ cells in chimpanzees.

Authors:  M Jonker; W Slingerland; G Treacy; P van Eerd; K Y Pak; E Wilson; S Tam; K Bakker; A F Lobuglio; P Rieber
Journal:  Clin Exp Immunol       Date:  1993-09       Impact factor: 4.330

8.  Comparative analysis of inflammatory infiltrates in collagen-induced arthritis, kidney graft rejection and delayed-type hypersensitivity in non-human primates.

Authors:  Margreet Jonker; Jacqueline Wubben; Krista Haanstra; Michel Vierboom; Bert 't Hart
Journal:  Inflamm Res       Date:  2012-10-13       Impact factor: 4.575

9.  Acquired resistance to type II collagen-induced arthritis in rhesus monkeys is reflected by a T cell low-responsiveness to the antigen.

Authors:  N P Bakker; M G van Erck; L A 't Hart; M Jonker
Journal:  Clin Exp Immunol       Date:  1991-11       Impact factor: 4.330

10.  The anti-arthritic and immunosuppressive effects of cyclosporin A on collagen-induced arthritis in the rhesus monkey.

Authors:  N P Bakker; N Van Besouw; R Groenestein; M Jonker; L A Hart
Journal:  Clin Exp Immunol       Date:  1993-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.